



KYOTEX AND INSILI.COM TO JOIN FORCES IN MOLECULE DISCOVERY SERVICES

Kyoto, Japan, and Zürich, Switzerland, April 24th, 2015 – KyoTex and inSili.com announce today that they have entered into a strategic molecule discovery and service partnership. Within the alliance, the two companies will perform joint research to discover bioactive agents with specific functional properties. In addition, KyoTex will provide support for inSili.com's ground-breaking drug discovery technologies to the Japanese market.

KYOTEX was founded in 2014 to provide scientific consulting and facilitation services between Japanese and international organizations. KyoTex has led the organization of major international scientific research meetings held in Japan, in addition to services offered for critical processing of large-scale molecular data in chemical and biological spaces. KyoTex is headquartered in Kyoto, Japan.

INSILI.COM was founded in 2013 as an ETH spin-off company to provide innovative molecular design and drug discovery services to the pharmaceutical, biotech and chemical industries. inSili.com's pioneering computational technology platform generates new molecular entities with multi-target activity profiles or designer selectivity. Their proprietary *de novo* molecular design and target prediction technology is based on revolutionary industry-proven technology to deliver "leads on demand". Located in Zürich, Switzerland, inSili.com supports international high-profile clients.

By merging the unique capabilities of the two companies, a matchless scientific service and research alliance will be implemented. The new strategic partnership will further strengthen inSili.com's consulting and discovery platform with a special focus on the Japanese market.

The collaborative platform will promote the design and identification of pharmaceutically and biologically active molecules to fuel sustained small molecule discovery.

" It is extremely exciting to announce this partnership with inSili.com. The combination of both companies' scientific expertise will be a cornerstone for innovative development. We are proud to provide our Japanese customers first-class support for their discovery projects using inSili.com's proven advanced technologies."

Dr. Etsuko Brown, CEO of KyoTex Co., Ltd.

"Progress is fuelled by strong and reliable partnerships. We are very happy to have won KyoTex as a member of our discovery alliance. KyoTex will not only strengthen our ties to the Japanese market but at the same time contribute valuable scientific expertise to our discovery projects."

Dr. Petra Schneider, CEO of inSili.com LLC

INSILI.COM LLC is a privately owned company founded as a spin-off from the Eidgenössische Technische Hochschule (ETH) Zürich, Switzerland. Its unique inSiliCode™ and CopyCATS™ molecular design technology offers rapid access to new chemical entities with desired properties. In addition to pursuing its own drug discovery projects, inSili.com provides scientific consulting and contract research services to the pharmaceutical, chemical and biotech industry. For further information, please visit www.insili.com.